Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos

INTRODUCTION: In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV- 2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. METHODS: We conducted a translati...

Full description

Saved in:

Bibliographic Details
Published in:	QJM
Main Authors:	Babalola, O E, Bode, C O, Ajayi, A A, Alakaloko, F M, Akase, I E, Otrofanowei, E, Salu, O B, Adeyemo, W L, Ademuyiwa, A O, Omilabu, S
Format:	Artigo
Language:	Inglês
Published:	Oxford University Press 2021
Subjects:	Original Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7928689/ https://ncbi.nlm.nih.gov/pubmed/33599247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/qjmed/hcab035
Tags:	Add Tag No Tags, Be the first to tag this record!

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos

Similar Items